Precigen Inc
PGEN1.764USD
+0.094+5.63%
交易中 （美东）报价延迟15分钟
520.62M总市值
亏损市盈率 TTM
关于 Precigen Inc 公司
Precigen, Inc. 是一家专注于发现和临床阶段的生物制药公司，致力于推进基因和细胞疗法。该公司的专有技术平台开发的产品候选物旨在针对其核心治疗领域（免疫肿瘤学、自身免疫性疾病和传染病）中的紧急和难治性疾病。该公司已开发出一系列针对多种适应症的疗法。该公司通过两个部门运营：生物制药和 Exemplar。生物制药部门主要由公司的法人实体 Precigen 和 ActoBio 以及来自非公司控制的公司的治疗和治疗平台的特许权使用费权益组成。Exemplar 部门由 Exemplar Genetics LLC 组成，以 Precigen Exemplar (Exemplar) 的名义开展业务，这是其全资子公司，专注于开发用于医疗保健研究应用的研究模型和服务。
公司简介
公司代码PGEN
公司名称Precigen Inc
上市日期Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
员工数量143
证券类型Ordinary Share
年结日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编20876
电话13015569900
网址https://precigen.com/
公司代码PGEN
上市日期Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
176.84K
+253.14%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
59.03K
+279.40%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
暂无数据
业务
地区
业务USD
名称
营收
占比
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Third Security, LLC
39.41%
Merck Serono SA
6.99%
Patient Capital Management, LLC
5.89%
Adage Capital Management, L.P.
3.82%
BlackRock Institutional Trust Company, N.A.
3.24%
Other
40.65%
持股股东
持股股东
占比
Third Security, LLC
39.41%
Merck Serono SA
6.99%
Patient Capital Management, LLC
5.89%
Adage Capital Management, L.P.
3.82%
BlackRock Institutional Trust Company, N.A.
3.24%
Other
40.65%
股东类型
持股股东
占比
Venture Capital
39.41%
Investment Advisor
15.26%
Corporation
6.99%
Hedge Fund
6.47%
Investment Advisor/Hedge Fund
5.43%
Individual Investor
3.56%
Research Firm
0.41%
Bank and Trust
0.06%
Insurance Company
0.04%
Other
22.36%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
296
229.13M
77.63%
-805.74K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
2023Q1
397
185.25M
75.25%
+14.81M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Third Security, LLC
116.34M
39.41%
-507.18K
-0.43%
Mar 31, 2025
Merck Serono SA
20.65M
6.99%
--
--
Mar 31, 2025
Patient Capital Management, LLC
17.37M
5.89%
-508.94K
-2.85%
Mar 31, 2025
Adage Capital Management, L.P.
11.28M
3.82%
+410.60K
+3.78%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.56M
3.24%
+209.48K
+2.24%
Mar 31, 2025
The Vanguard Group, Inc.
8.80M
2.98%
+465.47K
+5.59%
Mar 31, 2025
Iridian Asset Management LLC
4.59M
1.55%
-656.11K
-12.52%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.48M
1.18%
+179.75K
+5.45%
Mar 31, 2025
Sabzevari (Helen)
3.32M
1.12%
+557.91K
+20.22%
May 16, 2025
Parkman Healthcare Partners LLC
3.19M
1.08%
+3.19M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Inspire Small/Mid Cap ESG ETF
0.19%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Fidelity Enhanced Small Cap ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Inspire Small/Mid Cap ESG ETF
占比0.19%
iShares Micro-Cap ETF
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Fidelity Enhanced Small Cap ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
Global X Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
